نتایج جستجو برای: Samarium- 153

تعداد نتایج: 12920  

Journal: :Acta cirurgica brasileira 2009
Arthur Villarim Neto Maria Kadja Meneses Torres Açucena Kércia Regina Santos Gomes Pereira Amália Cínthia Meneses Rêgo Italo Medeiros Azevedo Mário Bernardo-Filho Aldo Cunha Medeiros

PURPOSE Many patients with metastatic bone disease have to use radiopharmaceuticals associated with chemotherapy to relieve bone pain. The aim of this study was to assess the influence of docetaxel on the biodistribution of samarium-153-EDTMP in bones and other organs of rats. METHODS Wistar male rats were randomly allocated into 2 groups of 6 rats each. The DS (docetaxel/samarium) group rece...

2011
Zohreh Naseri Amir Hakimi Amir R. Jalilian Ali Nemati Kharat Ali Bahrami-Samani Mohammad Ghannadi-Maragheh

Development of lanthanide detoxification agents and protocols is of great importance in management of overdoses. Due to safety of maltol as a detoxifying agent in metal overloads, it can be used as a lanthanide detoxifying agent. In order to demonstrate the biodistribution of final complex, [(153)Sm]-samarium maltolate was prepared using Sm-153 chloride (radiochemical purity >99.9%; ITLC and sp...

2012
Tomasz Skóra Teresa Kowalska Krystyna Zawiła

AIM OF THE STUDY Metastatic bone disease is a major clinical and therapeutic problem. It is particularly marked in patients with advanced breast and prostate cancer. Taking into account the diversity of the consequences of skeletal metastases, multidisciplinary patient care should be provided. Among the available treatment methods, radionuclide therapy plays a significant role. The goal of the ...

Journal: :Revista do Hospital das Clinicas 2004
Marcelo Tatit Sapienza Carla Rachel Ono Maria Inês Cury Guimarães Tomoco Watanabe Paulo Aguirre Costa Carlos Alberto Buchpiguel

PURPOSE The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. METHODS Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months af...

1998
Yuguo Du Robert J. Linhardt

A samarium-mediated Barbier reaction was performed to a€ord N-acetylneuraminic acid -Cglycosyl compounds (`` -C-glycosides'') in excellent yield. The neuraminic acid phenyl sulfone or 2-pyridyl sulfone derivatives reacted with ketones or aldehydes resulting in the instantaneous and stereospeci®c formation of Neu5Ac -C-glycosides. The phenyl and the 2-pyridyl sulfone derivatives were equally e€e...

Journal: :Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009
Saadia Skalli Marie-Dominique Desruet Jean-Cyril Bourre Jean-Pierre Caravel Jean-Philippe Vuillez

One of the current therapeutic approaches in the treatment of osteoblastic bone metastases uses the affinity of Samarium ((153)Sm) ethylene-diamine-tetramethylene phosphonic acid (EDTMP) for bone areas of bone turnover. As Samarium EDTMP is a beta-emitter, the radiotherapy contributes to osteoblastic bone lesion control over time. To date, the safety and effectiveness of Samarium therapy have n...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2008
D E Heron A Brufsky S Beriwal M Kurman

BACKGROUND The effect of prior treatment with radiotherapy and/or chemotherapy on the myelotoxicity of samarium lexidronam (Sm 153) in patients with metastatic bone lesions and bone pain was described. METHODS Single-institution retrospective chart review of patients receiving Sm 153. The effect of Sm 153 on peripheral white blood cell (WBC), platelet counts, and change from baseline was calc...

2013
John Longo Stephen Lutz Candice Johnstone

Bone metastases are prevalent among cancer patients and frequently cause significant morbidity. Oncology providers must mitigate complications associated with bone metastases while limiting therapy-related adverse effects and their impact on quality of life. Multiple treatment modalities, including chemotherapy, surgery, external beam radiation therapy, and radioisotopes, among others, have bee...

Journal: :Clinical advances in hematology & oncology : H&O 2013
Oliver Sartor

OS Radium-223 (Xofigo, Bayer and Algeta) is a boneseeking radiopharmaceutical that patients receive via injection. It is approved by the US Food and Drug Administration (FDA) to relieve pain and prolong survival in patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic evidence of bone metastasis. Because radium-223 selectively targets bone, it is not indicat...

2009
Marla Francisca dos Santos Rita Nely Vilar Furtado Monique Sayuri Konai Mario Luiz Vieira Castiglioni Renata Rosa Marchetti Jamil Natour

OBJECTIVES The aim of the present study was to investigate the effectiveness of Samarium(153)-particulate hydroxyapatite radiation synovectomy in rheumatoid arthritis patients with chronic knee synovitis. METHODS Fifty-eight rheumatoid arthritis patients (60 knees) with chronic knee synovitis participated in a controlled double-blinded trial. Patients were randomized to receive either an intr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید